Biweekly enzyme replacement therapy demonstrates efficacy in pediatric and adult hypophosphatasia while offering lower injection frequency.

Approval of the nonsteroidal mineralocorticoid receptor antagonist provides the first new treatment option in over 30 years for kidney disease in adults with type 1 diabetes.

Approvals for spinal muscular atrophy and chronic kidney disease; Joenja gains expanded approval in APDS; LSD derivative earns Breakthrough status to treat major depressive disorder; and zasocitinib ...

Phase 3 CELESTIMO study demonstrates significant progression free survival benefit for an mosunetuzumab combination regimen ...

Results from the final ORIGIN 3 analysis reveal that atacicept over 104 weeks significantly reduced the risk of a composite kidney disease progression event by 76% in adults with primary IgA ...

The sNDA approval provides clinicians with the first FDA-cleared photodynamic therapy for skin cancer, backed by phase 3 trial data demonstrating superior clinical and histologic clearance.

SAMA and SABA + SAMA use associated with increased risk for heart failure, arrhythmia, and mortality versus no use ...

Labeling update reduces required post-infusion monitoring time for initial doses from 22 to 24 hours to 6 to 8 hours in patients with extensive-stage small cell lung cancer.

Phase 3 COVER DFUS II trial data show the autologous therapy plus standard of care significantly improves wound closure rates at 12 weeks.

About 1.4 million Americans seek medical care after animal contact each year and roughly 100,000 receive rabies shots. Fewer than 10 people die. The CDC advises keeping away from wildlife, keeping ...

In the phase 3 LUNA trial, atogepant demonstrated a significant reduction in migraine days during the perimenstrual period compared with placebo.

All participating US comprehensive cancer centers report a shortage of at least 1 drug with 20% reporting 5 or more ...